KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Payables (2017 - 2025)

Novartis Ag's Payables history spans 9 years, with the latest figure at $5.1 billion for Q4 2025.

  • For Q4 2025, Payables fell 1.46% year-over-year to $5.1 billion; the TTM value through Dec 2025 reached $5.1 billion, down 1.46%, while the annual FY2025 figure was $5.1 billion, 1.46% down from the prior year.
  • Payables for Q4 2025 was $5.1 billion at Novartis Ag, down from $5.2 billion in the prior quarter.
  • Across five years, Payables topped out at $6.5 billion in Q4 2021 and bottomed at $5.1 billion in Q4 2025.
  • The 5-year median for Payables is $5.6 billion (2023), against an average of $5.7 billion.
  • The largest annual shift saw Payables grew 1.14% in 2021 before it dropped 7.64% in 2023.
  • A 5-year view of Payables shows it stood at $6.5 billion in 2021, then decreased by 6.87% to $6.0 billion in 2022, then dropped by 7.64% to $5.6 billion in 2023, then dropped by 6.05% to $5.2 billion in 2024, then decreased by 1.46% to $5.1 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Payables are $5.1 billion (Q4 2025), $5.2 billion (Q4 2024), and $5.6 billion (Q4 2023).